Trial Profile

A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clazakizumab (Primary) ; Alemtuzumab; Mycophenolate mofetil; Prednisone; Tacrolimus
Indications Renal transplant rejection
Focus Adverse reactions; Therapeutic Use

24 Mar 2025 Planned End Date changed from 30 Jul 2025 to 30 Aug 2025.
24 Mar 2025 Planned primary completion date changed from 30 Jul 2025 to 30 Aug 2025.
12 Mar 2024 Planned End Date changed from 30 Dec 2024 to 30 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com